Last reviewed · How we verify
Hypidone Hydrochloride tablets
Hypidone Hydrochloride tablets is a Small molecule drug developed by Zhejiang Huahai Pharmaceutical Co., Ltd.. It is currently in Phase 2 development. Also known as: HHT101.
Hypidone Hydrochloride tablets are used to treat Major Depressive Disorder, as indicated by a clinical study on ClinicalTrials.gov. The mechanism of action of Hypidone Hydrochloride is as a peptidoglycan inhibitor, according to ChEMBL.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hypidone Hydrochloride tablets |
|---|---|
| Also known as | HHT101 |
| Sponsor | Zhejiang Huahai Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects (PHASE1)
- Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets (PHASE2)
- To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hypidone Hydrochloride tablets CI brief — competitive landscape report
- Hypidone Hydrochloride tablets updates RSS · CI watch RSS
- Zhejiang Huahai Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Hypidone Hydrochloride tablets
What is Hypidone Hydrochloride tablets?
Who makes Hypidone Hydrochloride tablets?
Is Hypidone Hydrochloride tablets also known as anything else?
What development phase is Hypidone Hydrochloride tablets in?
Related
- Manufacturer: Zhejiang Huahai Pharmaceutical Co., Ltd. — full pipeline
- Also known as: HHT101
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing